Novel Pyridine-Based Fibroblast Activation Protein-Targeted Tracers: Design, Synthesis, and PET Imaging Evaluation for Tumors
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c02595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Ziyue Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Di…. Hauptthemen laut MEDLINE: Pyridines, Positron-Emission Tomography, Drug Design, Serine Endopeptidases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
To overcome the short tumor retention and nonspecific uptake of quinoline-based FAP inhibitors (e.g., FAP-46), we employed scaffold hopping to design novel phenylalanine-pyridyl-glycyl-prolamide derivatives. Among synthesized compounds (1a–i), multimeric derivatives 1h and 1i showed enhanced FAP affinity (IC50: 0.51 and 0.27 nM). In A549-FAP tumor models, [68Ga]1b exhibited higher tumor uptake (7.02% ID/g) and lower organ uptake than [68Ga]FAP-46, while [68Ga]1f demonstrated improved tumor retention (7.84% ID/g at 4 h) and high target-to-background ratios. [68Ga]1h/1i showed higher tumor uptake but increased nontarget accumulation. Specific FAP targeting was confirmed, and [68Ga]1f exhibited favorable hydrophilicity and stability. This work shows the phenylalanine-pyridyl-glycyl-prolamide scaffold is a viable alternative to quinoline-based ones, with [68Ga]1f promising for clinical PET imaging and [68Ga]1h/1i for radioligand therapy, providing a new direction for FAP-targeted radiopharmaceuticals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China.
- Department of Nuclear Medicine, National Cancer center/National Clinical Research Center for cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518…
- School of Pharmaceutical Science, Capital Medical University, Beijing 100069, China.
- Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, No. 45 Changchun St, Xicheng District, Beijing 100053, China.
ORCID-Profile: Yong Huang, Zehui Wu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Yu, Z., Huang, Y., Jiang, Z., Chen, H., Cheng, X., Liu, Y., Liang, Y., & Wu, Z. (2025). Novel Pyridine-Based Fibroblast Activation Protein-Targeted Tracers: Design, Synthesis, and PET Imaging Evaluation for Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02595
Vancouver
Yu Z, Huang Y, Jiang Z, Chen H, Cheng X, Liu Y, et al. Novel Pyridine-Based Fibroblast Activation Protein-Targeted Tracers: Design, Synthesis, and PET Imaging Evaluation for Tumors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02595
BibTeX
@article{Yu2025,
author = {Yu, Ziyue and Huang, Yong and Jiang, Zeng and Chen, Hualong and Cheng, Xuebo and Liu, Yajing and Liang, Ying and Wu, Zehui},
title = {Novel Pyridine-Based Fibroblast Activation Protein-Targeted Tracers: Design, Synthesis, and PET Imaging Evaluation for Tumors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c02595}
}
EUVIMED